Bio-Rad Laboratories (BIO) Cost of Revenue (2009 - 2026)

Bio-Rad Laboratories (BIO) has reported Cost of Revenue for 18 consecutive years, with $305.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cost of Revenue changed 0.36% year-over-year to $305.2 million in Q2 2026; TTM through Jun 2026 was $1.2 billion, a 3.35% increase from a year earlier, with the FY2025 full-year figure at $1.2 billion, up 4.69% from the prior year.
• Cost of Revenue was $305.2 million for Q2 2026 at Bio-Rad Laboratories, up from $282.7 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $348.0 million in Q4 2025 and troughed at $279.4 million in Q1 2025.
• A 5-year average of $305.4 million and a median of $305.8 million in 2025 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue declined 11.06% in 2024 and increased 8.08% in 2025, its largest moves.
• Over 5 years, Cost of Revenue stood at $333.2 million in 2022, then dropped by 5.51% to $314.8 million in 2023, then gained by 3.43% to $325.6 million in 2024, then grew by 6.88% to $348.0 million in 2025, then retreated by 12.3% to $305.2 million in 2026.
• The last three Cost of Revenue figures came in at $305.2 million (Q2 2026), $282.7 million (Q1 2026), and $348.0 million (Q4 2025), per Business Quant data.